Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382099 | 0.91 | RAB9A (0.50) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL31039595 | 0.87 | MEN1 (0.51) | RAB9AALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL476742 | 0.87 | MEN1 (0.51) | RAB9AALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL24543271 | 0.82 | MAPT (0.55) | RAB9AALDH1A1NPC1POLBLMNA | |
| SCHEMBL29368311 | 0.82 | MAPT (0.55) | RAB9AALDH1A1NPC1POLBLMNA | |
| SCHEMBL6298255 | 0.81 | MEN1 (0.48) | RAB9AALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL30725849 | 0.81 | MAPT (0.57) | RAB9AALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL19961720 | 0.79 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL29741029 | 0.77 | MAPT (0.43) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL9926875 | 0.76 | RAB9A (0.57) | RAB9AALDH1A1SMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2012-06-14 | — | — | US | disclosed |
| WO-2009021747-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, ACVR2B, CPT1B | RAB9A 2122/4885ALDH1A1 199/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.